Ideas to action: independent research for global prosperity
Search
Filters:
Experts
Facet Toggle
Topics
Facet Toggle
Content Type
Facet Toggle
Publication Type
Facet Toggle
Time Frame
Facet Toggle
Multimedia
September 12, 2023
The first of CGD's conversations with candidates for the presidency of the European Investment Bank was with Margrethe Vestager. Margrethe is the Executive Vice-President of the European Commission and Commissioner for Competition. She has had a long and illustrious political career, having become a...
POLICY PAPERS
February 10, 2023
Bangladesh’s Primary Education Stipend Program provides stipends for 13 million primary schoolchildren to 10 million mothers. In 2017 the method of payment changed from cash to mobile money. This study considers the experience of the mothers with the shift to mobile money, and to the change in payme...
Blog Post
January 19, 2023
Kenya has become a poster child for digitally driven development. Known as “Silicon Savannah,” the country has a multi-billion-dollar tech industry that routinely produces startups. Among its most prominent successes is M-Pesa. Launched in 2007, the mobile wallet service revolutionized how Kenyans t...
POLICY PAPERS
January 19, 2023
This study surveys Kenya's electronic payment system for social benefits, Inua Jamii, from the perspective of recipients, including their views on convenience and the benefits from competition. It also considers whether these digital G2P payments programs have increased financial inclusion more gene...
Blog Post
December 14, 2022
It’s clear that COVID-19 oral antivirals are effective, and recent deals have made them even cheaper for African countries. But should these countries be investing in these medicines? Or would spending on alternative health services be better value for money? Unfortunately, there is very little avai...
Blog Post
December 14, 2022
Four new CGD pieces, released today, examine the current state of play on COVID-19 oral antivirals. Our analyses provide a deep-dive in key cross-cutting areas—demand, voluntary licensing deals for generic supply, and deployment—and offer policy actions for 2023 and beyond.